In contrast, 43.5% biochemical progression was reported in a study of 108 men with recurrent prostate carcinoma and PSMA-guided, normo-, or moderate hypofractionated radiotherapy after a median follow-up of 18 months [23]. This evidence concerns the gene FOLH1 and prostate carcinoma.